Unlock the Editor’s Digest for free
Roula Khalaf, Editor of the FT, selects her favourite stories in this weekly newsletter.
**Key Takeaways**
1. **Labour Market Strain & Fiscal Risk:** The significant decline in UK “healthy life expectancy” (HLE), particularly driven by worsening mental health among younger demographics, signals a material long-term risk to labour supply, workforce productivity, and economic growth. This trend places increased demand on social welfare and healthcare systems, posing fiscal challenges for the government and potentially straining pension funds.
2. **Misleading Economic Indicators:** Relying on broad, subjective metrics like HLE can obscure critical underlying economic and social trends. Such imprecision risks leading to misinformed policy decisions, suboptimal capital allocation by investors across sectors (from healthcare to insurance and human capital development), and flawed ESG assessments.
3. **Shifting Investment & Policy Focus:** The true crisis—rising mental health challenges, predominantly among young adults and women—highlights a crucial pivot point. It necessitates targeted policy interventions and creates significant investment opportunities in mental health services, digital therapeutics, and workplace wellness programs, while simultaneously signaling risks to traditional pension models and the future quality of the workforce.
The recent revelation that the UK’s “healthy life expectancy” (HLE) has sharply declined from just over 63 in 2019 to 61 by 2023 is far more than a public health concern; it’s a flashing red signal for economic stability, productivity, and long-term fiscal planning. This erosion of population health quality, if accurately diagnosed, poses a material risk to the nation’s human capital, labour market resilience, and the sustainability of its welfare state, as analysis by the Health Foundation think-tank underscores.
In market terms, a diminishing HLE translates directly into a shrinking pool of healthy, productive workers, exacerbating existing labour shortages and inflationary pressures. It forecasts increased demand on the National Health Service (NHS), potentially diverting significant public funds away from growth-driving investments, and placing greater strain on public and private pension schemes as individuals potentially exit the workforce earlier due to ill health. For insurers, this trend mandates a reassessment of risk models and premium structures across health, life, and disability policies. The implication for GDP growth, already hampered by an aging population and post-Brexit labour adjustments, is undeniably negative.
Yet, while the *idea* of measuring quality of life is sound, the methodology behind ‘healthy life expectancy’ (HLE) presents a significant analytical challenge for investors and policymakers alike. As a crude amalgam of precise demographic data (life expectancy – arguably the most robust demographic statistic) and subjective self-reported health, its inherent volatility and inconsistencies globally render it a potentially misleading economic signal. Consider the European Union’s data, which places Bulgaria second highest out of 27 countries for HLE, despite ranking third lowest for core life expectancy. If that isn’t puzzling enough, the very international rankings for HLE, from bodies like the WHO, are themselves inconsistent, both in absolute levels and reported direction of travel.
Investors seeking to understand national productivity, healthcare demand, or even the efficacy of social policy risk misallocating capital if they rely on such an imprecise barometer. These issues are well understood by researchers. First, subjective data is inherently less robust than objective mortality records. The Office for National Statistics’ own annual survey, used for its HLE measure, showed a decline in “good” self-reported health between 2011 and 2021, while the decennial census paradoxically indicated an improvement over the same period. Such discrepancies, arising from differences in scale, coverage, timing, and survey delivery mode, undermine the reliability of the headline number for serious economic analysis.
Then there is the issue of cultural and social biases influencing self-assessment. What constitutes “good health” can vary significantly across demographics and national borders, and even between generations within the same country. Researchers have known for decades that reporting of health problems and disability is influenced by these variations. Failing to account for these differing reporting styles can yield fundamentally misleading results, making cross-country comparisons – and thus international investment decisions based on such data – highly suspect. How can ‘social’ factors in Environmental, Social, and Governance (ESG) investing frameworks accurately reflect national wellbeing if the underlying data is so fundamentally flawed and inconsistent?
But arguably more important than these technical flaws is the fact that even a perfect picture of healthy life expectancy data crams several disparate stories into one: it obscures more than it reveals. Here again, the case of the UK is illustrative. If we drill down into more detailed data on people’s health conditions, we find that over recent years physical health has been stable or improving for all age groups. The deterioration in overall self-rated health is coming almost entirely from answers to questions about mental health, especially among young adults.
This recalibration of the problem statement has profound implications for market participants. For the labour market, this is not just about a shrinking workforce, but a workforce facing distinct challenges. Mental health issues can lead to increased presenteeism (working while unwell, reducing productivity), absenteeism, and higher rates of early career attrition. This impairs human capital development, a critical driver of long-term economic competitiveness. Companies, particularly those in knowledge-based industries reliant on innovation and creativity, face higher costs related to employee support, retention, and recruitment. On the flip side, this trend sparks significant investment opportunities: the mental health tech sector, digital therapeutics, corporate wellness programs, and specialised healthcare providers are poised for substantial growth. Pharmaceutical companies focused on neurological and psychiatric drugs may also see increased demand, shifting investment away from traditional physical health interventions.
Moreover, the concentration of mental health issues among the younger demographic has long-term ramifications for pension funds and social security systems. If early career mental health challenges persist, they could translate into reduced lifetime earnings, lower pension contributions, and a greater likelihood of relying on state support later in life, exacerbating intergenerational fiscal burdens. Real estate developers might increasingly consider proximity to green spaces and mental health support infrastructure as factors influencing property value and desirability for a health-conscious workforce.
Reading that “UK healthy life expectancy falls from 63 to 61” conjures images of ailing sixtysomethings and discussions about chronic or debilitating disease from middle age. But this is a misreading of the true situation, facilitated by a clunky measure that, as researchers have observed, struggles to accurately capture a multi-faceted global trend where health problems and mortality are less concentrated on the elderly. “Britons’ physical health holds up quite well, but younger adults and young women in particular are reporting increasing mental health problems” may be a mouthful, but it’s a much more accurate summary of what the underlying data actually shows. And one that could guide the policy debate towards solutions that have a chance of working, and investors towards opportunities that genuinely address evolving societal needs and risks.
[email protected], @jburnmurdoch
Market Impact
The decline in UK healthy life expectancy, particularly when re-contextualized as a surge in youth mental health challenges, carries significant market implications:
- Labour Market Disruption: Expect continued pressure on labour supply and productivity across UK industries, potentially contributing to wage inflation and limiting economic expansion. Businesses will likely face increased costs for employee wellbeing initiatives, mental health support, and retention efforts to mitigate presenteeism and absenteeism.
- Investment Reallocation: Capital will increasingly shift towards mental health services, digital therapeutics, and corporate wellness solutions. Investors should scrutinize health sector portfolios for exposure to these growth areas and reassess traditional healthcare plays that may not align with the evolving health landscape. There’s also a rising demand for data analytics and AI-driven solutions to better diagnose and manage mental health.
- Fiscal and Pension Strain: Governments will face escalating demands for public health and welfare spending, particularly for mental health infrastructure and support for younger generations, potentially requiring higher taxation or increased borrowing. Pension funds and insurers must recalibrate long-term liabilities and risk assessments to account for a potentially less healthy and shorter working-life population.
- ESG Scrutiny: Sophisticated investors will demand more granular and reliable social metrics (the “S” in ESG) that accurately reflect population health nuances. Moving beyond crude aggregates to assess true human capital risks and opportunities, particularly in workforce mental health, will become critical for responsible investment.